FilingReader Intelligence
Shanghai Shyndec subsidiaries secure drug registration certificates
July 28, 2025 at 09:10 AM UTC•By FilingReader AI
Shanghai Shyndec Pharmaceutical announced its subsidiaries Sinopharm RongSheng and Sinopharm Accord received drug registration certificates.
RongSheng obtained approval for hypertension treatment Midapride Hydrochloride Tablets, targeting a 25.45 million yuan market. Accord received approval for cancer therapy drug Calcium Leucovorin Injection, addressing a 95.10 million yuan market.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600420•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Shanghai Shyndec Pharmaceutical publishes news
Free account required • Unsubscribe anytime